Crìa addresses the urgent need for safer, more sustainable, and efficient ultra-low temperature (ULT) portable solutions in the biopharma cold chains. Current methods rely on dry ice, which pose safety risks, regulatory challenges, and environmental concerns. Our innovation replaces dry ice with advanced phase change materials (PCMs), ensuring reliable temperature control while reducing carbon footprint.
Led by experts in vacuum thermal insulation with over 25 years of experience, we leverage patented technology to pioneer the first dry ice-free PCM ULT shippers. The last mile biopharma cold chain market is projected to reach $14B by 2030, driven by next-gen therapies.
